BeOne Medicines (ONC) Short-term Investments (2015 - 2023)
BeOne Medicines (ONC) posted quarterly Short-term Investments of $2.6 million for Q4 2023, down 99.61% year-over-year from $665.3 million in Q4 2022, and down 97.57% quarter-over-quarter from $107.0 million in Q3 2023.
BeOne Medicines (ONC) Short-term Investments (2015 - 2023) Analysis & Trends
BeOne Medicines (ONC) has reported Short-term Investments for 9 consecutive years, with $2.6 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Short-term Investments fell 99.61% year-over-year to $2.6 million; the TTM figure through Dec 2023 stood at $2.6 million (down 99.61% YoY), while the FY2023 annual figure was $2.6 million, down 99.61% from the prior year.
- Short-term Investments slipped to $2.6 million in Q4 2023 per ONC's latest filing, from $107.0 million in the prior quarter.
- Across five years, Short-term Investments topped out at $3.3 billion in Q4 2020 and bottomed at $2.6 million in Q4 2023.
- Historically, Short-term Investments has averaged $1.4 billion across 5 years, with a median of $1.0 billion in 2022.
- Annual changes were most pronounced in 2020 — Short-term Investments soared 796.21% — and 2023, when it tumbled 99.61%.
- BeOne Medicines' Short-term Investments stood at $364.7 million in 2019, then jumped by 796.21% to $3.3 billion in 2020, then sank by 31.41% to $2.2 billion in 2021, then tumbled by 70.33% to $665.3 million in 2022, then sank by 99.61% to $2.6 million in 2023.
- Business Quant data shows ONC's Short-term Investments at $2.6 million in Q4 2023, $107.0 million in Q3 2023, and $105.7 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 2.60 Mn |
| Sep 30, 2023 | 106.99 Mn |
| Jun 30, 2023 | 105.69 Mn |
| Mar 31, 2023 | 294.06 Mn |
| Dec 31, 2022 | 665.25 Mn |
| Sep 30, 2022 | 872.00 Mn |
| Jun 30, 2022 | 1.17 Bn |
| Mar 31, 2022 | 1.90 Bn |
| Dec 31, 2021 | 2.24 Bn |
| Sep 30, 2021 | 2.53 Bn |
| Jun 30, 2021 | 2.61 Bn |
| Mar 31, 2021 | 2.91 Bn |
| Dec 31, 2020 | 3.27 Bn |
| Sep 30, 2020 | 3.25 Bn |
| Jun 30, 2020 | 1.81 Bn |
| Mar 31, 2020 | 1.42 Bn |
| Dec 31, 2019 | 364.73 Mn |
| Sep 30, 2019 | 375.77 Mn |
| Jun 30, 2019 | 618.80 Mn |
| Mar 31, 2019 | 849.17 Mn |